Velagliflozin in Cats

Velagliflozin is an oral diabetes medication for cats sold under the brand name Senvelgo. In the United States, it is FDA approved to improve glycemic control in otherwise healthy cats with diabetes mellitus that have not previously been treated with insulin. That point matters. This medication is not meant for every diabetic cat, and it should not be started without careful screening and a treatment plan from your vet.

Velagliflozin belongs to a newer class of drugs called SGLT2 inhibitors. Instead of replacing insulin, it lowers blood glucose by helping the kidneys pass more glucose into the urine. For some newly diagnosed cats, that can improve excessive thirst, increased urination, weight loss, and appetite changes without daily insulin injections. Merck notes that oral SGLT2 inhibitors can improve blood glucose, fructosamine, and clinical signs in newly diagnosed diabetic cats, and velagliflozin has shown strong results in published veterinary data.

Even so, convenience does not mean low risk. FDA safety communications emphasize that cats on Senvelgo can develop diabetic ketoacidosis, including euglycemic diabetic ketoacidosis, where blood sugar may look normal even during a life-threatening emergency. Because of that, your vet has to decide whether your cat is an appropriate candidate based on history, exam findings, and lab work.

For pet parents, the big takeaway is balance. Velagliflozin can be a useful option for the right cat, but it requires screening, follow-up, and fast action if appetite drops or vomiting, lethargy, diarrhea, weakness, or dehydration appear. See your vet immediately if those signs develop while your cat is taking this medication.

Velagliflozin blocks sodium-glucose cotransporter 2 proteins in the kidney. These transporters normally reabsorb filtered glucose back into the bloodstream. When they are inhibited, more glucose leaves the body in the urine, which lowers blood glucose concentrations. Merck describes this as increased urinary glucose excretion from reduced glucose resorption in the proximal renal tubule.

That mechanism is different from insulin therapy. Insulin helps move glucose from the bloodstream into cells and is essential for cats with insulin-dependent diabetes. Velagliflozin does not replace insulin, so it should only be used in cats that still make enough of their own insulin. This is why FDA and Merck both stress that SGLT2 inhibitors are for selected newly diagnosed cats and are contraindicated in cats previously treated with insulin or cats with insulin-dependent diabetes.

In the FDA approval summary, Senvelgo was dosed at 1 mg/kg by mouth once daily and showed the expected pharmacologic effect of glucosuria, meaning glucose spilling into the urine. Field study data summarized by FDA and Merck found that more than 80% of treated cats had improved glycemic control over 6 months, with many also showing improvement in diabetic signs at home.

Because the drug works through the kidneys and changes how the body handles glucose and ketones, monitoring is not optional. Your vet may recommend repeat bloodwork, urinalysis, ketone checks, body weight tracking, and reassessment of appetite and hydration, especially during the first weeks of treatment.

The most important safety concern with velagliflozin is diabetic ketoacidosis, often shortened to DKA. Cats taking Senvelgo can also develop euglycemic DKA, which means dangerous ketoacidosis may happen even when the blood glucose is not dramatically high. FDA warns that this can be fatal and may be missed if a team assumes normal glucose rules out a diabetic emergency. See your vet immediately if your cat becomes weak, stops eating, vomits, has diarrhea, seems dehydrated, or becomes unusually quiet or lethargic.

Other concerns include pancreatitis risk, poor appetite, weight loss, dehydration, and possible urinary tract infections. FDA also advises caution in cats with kidney, liver, or pancreatic disease, and VCA notes the drug should be avoided in cats with a recent history of pancreatitis or liver disease. If ketones are found in the urine, FDA advises stopping Senvelgo and promptly treating with insulin, even if the blood glucose is normal.

Some cats may also have vomiting, diarrhea, or reduced appetite that does not turn into DKA but still needs prompt veterinary attention. Because diabetic cats can decline quickly, your vet may tell you to stop the medication while your cat is being evaluated. This is especially important during times of poor food intake, illness, or surgery, when the risk of metabolic complications can rise.

Allergic reactions appear to be uncommon, but VCA advises watching for facial swelling, rash, fever, or breathing changes. Any unusual sign after starting a new medication deserves a call to your vet. With velagliflozin, early recognition matters more than waiting to see if the problem passes on its own.

The FDA approval summary lists the Senvelgo dose as 0.45 mg/lb, which is 1 mg/kg, by mouth once daily. The oral solution concentration is 15 mg/mL. It should be given at about the same time each day, regardless of blood glucose level. The medication may be given directly into the mouth or with a small amount of wet food, but the label says not to mix it into food.

If a dose is missed, the FDA summary says it should be given as soon as possible on the same day. If the cat vomits within 30 minutes of dosing, the dose can be repeated. Pet parents should not change the dose, stop insulin to switch medications, or restart the drug after a problem without instructions from their vet.

Before starting treatment, your vet will usually confirm that your cat is a good candidate. That often includes bloodwork, urinalysis, ketone assessment, and screening for kidney, liver, or pancreatic disease. Cats that are dehydrated, lethargic, anorexic, previously treated with insulin, or suspected to have insulin-dependent diabetes are not appropriate candidates based on FDA safety guidance.

Once treatment begins, follow-up visits are part of the plan. Your vet may monitor blood glucose, fructosamine, ketones, body weight, appetite, hydration, and sometimes pancreatic and liver values. If control is poor early in treatment or ketones rise, your vet may recommend stopping velagliflozin and moving to insulin-based care instead.

Published veterinary interaction data for velagliflozin are still limited compared with older feline medications, so your vet should review every prescription, supplement, and over-the-counter product your cat receives. VCA lists several medication groups that should be used with caution alongside velagliflozin, including ACE inhibitors, antihypertensive drugs, beta-blockers, corticosteroids, diuretics, estrogens or progestogens, and glipizide.

Some of these combinations matter because they can affect hydration, blood pressure, kidney perfusion, or blood glucose control. For example, diuretics and some blood pressure medications may increase the chance of dehydration or low blood pressure in a cat already losing glucose and water through the urine. Corticosteroids can raise blood glucose and make diabetic control harder. Glipizide also changes glucose regulation, so combining therapies may complicate monitoring.

FDA also warns that Senvelgo contains propylene glycol and should be used cautiously with other products that contain propylene glycol. At the labeled dose, cats receive 40 mg/kg/day of propylene glycol from Senvelgo, and exceeding 80 mg/kg/day may increase the risk of excess hepatic glycogen stores.

The safest approach is practical and thorough. Bring a full medication list to each visit, including flea and tick products, supplements, appetite stimulants, steroids, and any recent emergency medications. If another veterinarian sees your cat urgently, let them know your cat is taking velagliflozin so euglycemic DKA is not overlooked.